Search the Newsreel

NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen

Wall Street Zen has downgraded Avalyn Pharma (NASDAQ:AVLN) from a "hold" to a "sell" rating, despite the overall analyst sentiment being a "Moderate Buy" with a $60 average price target. Other firms like Jefferies, Guggenheim, and Evercore have issued "buy" or "outperform" ratings, while …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

(RIGL) Price Dynamics and Execution-Aware Positioning

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …

Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen

Wall Street Zen has upgraded Ascendis Pharma A/S (NASDAQ:ASND) from a "hold" to a "buy" rating, aligning with a consensus "Buy" rating and an average price target of $299.24 from other analysts. The company's shares opened 0.9% higher at $248.50, and it recently reported …

Vaishali Pharma standalone net profit rises 16.41% in the June 2026 quarter

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside

The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing …

Hansoh Pharmaceutical Group Stock Sheds 1.7% in Hong Kong

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N

Kiniksa Pharmaceuticals International, plc (BIVA:KNSA/N) generated 12.21 billion MXN in revenue last year, primarily from its Therapeutic Medicines segment. The United States was the largest contributor to this revenue, accounting for 12.20 billion MXN. This represents an increase from the previous year's segment revenue …

Quoin Pharmaceuticals | 10-Q: Quarterly report

This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.

Allspring Emerging Growth Fund's Ascendis Pharma AS(ASND) Holding History

Cue Biopharma CEO Lin sells shares worth $1.6 million

Cue Biopharma CEO Lin Shao-Lee sold shares worth $1.6 million between August 12 and 13, 2026, to cover tax obligations from vested restricted stock units, not as discretionary sales. Concurrently, Mr. Lin acquired 109,179 shares through the vesting of performance stock units. The company …

Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?

Lexicon Pharmaceuticals (LXRX) has completed enrollment in its Phase III SONATA HCM trial for sotagliflozin, with positive momentum from regulatory updates and partner collaborations. The company is considered 38% undervalued by some narratives, trading at $2.34 against a fair value of $3.77 per share, …

Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A

Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above …

Nicola Greenway (TAK) plans sale of 12,980 Takeda ADSs after RSU vesting

Nicola Greenway has filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, derived from vested Restricted Stock Unit Awards. The planned sale is scheduled for August 14, 2026, through Interactive Brokers LLC. This follows previous sales on August …

Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?

Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals

Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax …

Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 9.5% beneficial ownership stake in Traws Pharma, Inc., totaling 1,555,423 shares of common stock. This figure includes 1,077,281 shares issuable upon the exercise of warrants within 60 days, subject to a 9.99% beneficial ownership limitation. …

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as …

Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical …

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $(0.44) EPS, significantly missing the consensus estimate of $(0.09) by $0.35. Following the announcement, shares of NRXP fell 2.1% to $3.27. Despite the earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of …

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares